

AMENDMENTS

Listing of Claims

This listing of claims will replace all prior versions and listings of claims in the application:

1. (Currently amended) ~~[[A]]An isolated peptide that targets a tumor cell, wherein said peptide comprises HN-1, a variant of HN-1, or a HN-1 related peptide, each comprising the amino acid sequence of comprising SEQ ID NO:1.~~
2. (Canceled)
3. (Original) The peptide of claim 1, consisting of SEQ ID NO:1.
- 4-6. (Canceled)
7. (Currently amended) A composition comprising:
 - a) ~~[[a]]an anti-cancer drug; and~~
 - b) a peptide that targets a tumor cell, wherein said peptide comprises ~~HN-1, a variant of HN-1, or a HN-1 related peptide, each comprising the amino acid sequence of comprising SEQ ID NO:1.~~
8. (Canceled)
9. (Original) The composition of claim 7, wherein said peptide consists of SEQ ID NO:1.
10. (Original) The composition of claim 7, wherein said drug is a chemotherapeutic agent.
11. (Original) The composition of claim 7, wherein said drug is a cytotoxic agent.
12. (Original) The composition of claim 7, wherein said drug is an apoptotic agent.

13. (Original) The composition of claim 7, wherein said drug is a DNA-damaging agent.
14. (Currently amended) The composition of claim 7, wherein said drug is plant alkyloidalkaloid.
15. (Original) The composition of claim 7, wherein said drug is cisplatin (CDDP), carboplatin, procarbazine, mechlorethamine, cyclophosphamide, ifosfamide, melphalan, chlorambucil, bisulfan, nitrosurea, dactinomycin, daunorubicin, doxorubicin, bleomycin, plicomycin, mitomycin, etoposide (VP16), tamoxifen, transplatinum, 5-fluorouracil, vincristin, vinblastin or methotrexate.

16-85. (Canceled)

86. (Previously presented) The peptide of claim 1, wherein said peptide is internalized by said tumor cell.
87. (Previously presented) The composition of claim 7, wherein said peptide is internalized by said tumor cell.
88. (Currently amended) The composition of claim 14, wherein said plant alkyloidalkaloid is paclitaxel.